

Lead selection and optimization of therapeutic anti-CD40 antibody for the treatment of multiple sclerosis

PB immune therapeutics



IMMUNOLOGY	Lead
Product Type	Immunoglobulin product (mAb)
Indication	1st indication: Multiple sclerosis 2nd indication: Pemphigus
Target	Human CD40
MoA (Mechanism of Action)	<p style="text-align: center;">Blocking Signal Transduction Using Anti-CD40 Antibodies</p> <p>DC activity inhibition</p> <ul style="list-style-type: none"> • DC maturation ↓ • Enhanced survival ↓ • Inflammatory cytokine secretion ↓ <p>B cell activity inhibition</p> <ul style="list-style-type: none"> • Activation & differentiation ↓ • Antibody production ↓ • Isotype switch ↓ <p>Macrophage activity inhibition</p> <ul style="list-style-type: none"> • Enhanced activation ↓ • Cytokine secretion ↓
Competitiveness	-
Development Stage	Lead
Route of Administration	Intravenous